GlassScriptPhysician profile
Arnie B Tannenbaum
NPI 1952348971
$1,523.81
in general payments reported to CMS, 2019-2025
24 companies · $320 in 2025
The $320 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $65.00 · 2021: $128 · 2022: $274 · 2023: $491 · 2024: $142 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $260.01 | 2021-2024 | Axonics |
| Astellas Pharma US INC | $234.12 | 2019-2025 | Xtandi |
| Procept Biorobotics Corporation | $224.46 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Janssen Biotech, INC. | $190.71 | 2023 | Erleada |
| Teleflex LLC | $97.13 | 2023 | Urolift |
| Telix Pharmaceuticals | $59.78 | 2024-2025 | Illuccix |
| Coloplast Corp | $49.34 | 2024 | |
| Becton, Dickinson and Company | $46.32 | 2025 | Bard Urinary Drainage Bag |
| Endo Pharmaceuticals INC. | $40.66 | 2020 | |
| Urogen Pharma, INC. | $36.71 | 2020-2022 | |
| Tolmar Pharmaceuticals, INC. | $32.84 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.86 | 2023 | |
| Abbvie INC. | $25.09 | 2023 | Botox |
| Calyxo, INC. | $23.78 | 2025 | Cvac Aspiration System |
| Olympus America INC. | $21.56 | 2023 | Itind System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.18 | 2022 | |
| Sumitomo Pharma America, INC. | $19.96 | 2023 | Gemtesa |
| Myovant Sciences INC. | $18.85 | 2022 | |
| Myriad Genetic Laboratories, INC. | $18.83 | 2022 | |
| Urovant Sciences INC | $18.83 | 2022 | |
| Medtronic, INC. | $15.13 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.73 | 2024 | Adstiladrin |
| Accord Healthcare, INC. | $14.13 | 2023 | |
| Neotract INC. | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnie Tannenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.